Classification of prostatic diseases by means of multivariate analysis on in vivo proton MRSI and DCE-MRI data

NMR in Biomedicine

Volumn 22, Issue 10, 2009, Pages 1036-1046

  Valerio, Mariacristina ^a   Panebianco, Valeria ^a   Sciarra, Alessandro ^a   Osimani, Marcello ^a   Salsiccia, Stefano ^a   Casciani, Lorena ^a   Giuliani, Alessandro ^b   Bizzarri, Mariano ^a   Silverio, Franco Di ^a   Passariello, Roberto ^a   Conti, Filippo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Cancer; Differential diagnosis; Dynamic contrast enhanced MRI; Medical imaging; Metabolomics; Multivariate analysis; Prostatic diseases; Proton magnetic resonance spectroscopic imaging

Indexed keywords

DIFFERENTIAL DIAGNOSIS; DYNAMIC CONTRAST ENHANCED MRI; MAGNETIC RESONANCE SPECTROSCOPIC IMAGING; METABOLOMICS; MULTI VARIATE ANALYSIS;

DECISION MAKING; DIAGNOSIS; MAGNETIC RESONANCE SPECTROSCOPY; MEDICAL IMAGING; METABOLISM; NUCLEAR MAGNETIC RESONANCE; PROTONS; RESONANCE; SPECTROSCOPIC ANALYSIS; SPIN POLARIZATION;

MULTIVARIANT ANALYSIS;

ARTICLE; CHRONIC INFLAMMATION; COMPUTER ASSISTED DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DYNAMIC CONTRAST ENHANCED NUCLEAR MAGNETIC RESONANCE IMAGING; FIBROSIS; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE PROCESSING; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE DISEASE; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY;

BIOPSY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MULTIVARIATE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; PROSTATIC DISEASES;

EID: 73349126096     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1408     Document Type: Article

References (59)

1. Cooperberg MR, Lubeck DP, Grossfeld GD, Mehta SS, Carroll PR. Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavour. J. Urol. 2002; 168: 491-495.
2. Müeller-Lisse UG, Scherr MK. Proton MR spectroscopy of the prostate. Eur. Radiol. 2007; 63: 351-360.
3. Westphalen AC, McKenna DA, Kurhanewicz J, Coakley FV. Role of magnetic resonance imaging and magnetic resonance spectroscopic imaging before and after radiotherapy for prostate cancer. J. Endourol. 2008; 22: 789-794.
4. Stephan C, Büker N, Cammann H, Meyer HA, Lein M, Jung K. Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity. BMC Urol. 2008; 2: 8-10.
5. Shukla-Dave A, Hricak H, Eberhardt SC, Olgac S, Muruganandham M, Scardino PT, Reuter VE, Koutcher JA, Zakian KL. Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings-initial observations. Radiology 2004; 231: 717-724.
6. Oesterling JE, Jacobsen SJ, Chute CG. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993; 270: 860-866.
7. Flanigan RC, Catalona WJ, Richie JP, Ahmann FR, Hudson ML, Scardino PT, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC. Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. J. Urol. 1994; 152: 1506-1509.
8. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J. Urol. 1997; 157: 199-203.
9. Chon CH, Lai FC, McNeal JE, Presti JC, Jr. Use of extended systematic sampling in patients with a prior negative prostate needle biopsy. J. Urol. 2002; 167: 2457-2460.
10. Pepe P, Aragona F. Prostate needle biopsy: 12 vs. 18 cores: is it necessary? Urol. Int. 2005; 74: 19-22.
11. Samir S, Taneja MD. Prostate biopsy: targeting cancer for detection and therapy. Rev. Urol. 2006; 8: 173-182.
12. Müller-Lisse UL, Hofstetter A. Urological diagnosis of prostate carcinoma. Radiologe 2003; 43: 432-440.
13. Okamura T, Umemoto Y, Yamashita K, Suzuki S, Shirai T, Hashimoto Y, Kohri K. Pitfalls with MRI evaluation of prostate cancer detection: comparison of findings with histopathological assessment of retropubic radical prostatectomy specimens. Urol. Int. 2006; 77: 301-306.
14. Hom JJ, Coakley FV, Simko JP, Qayyum A, Lu Y, Schmitt L, Carroll PR, Kurhanewicz J. Prostate cancer: endorectal MR imaging and MR spectroscopic imaging-distinction of true-positive results from chance-detected lesions. Radiology 2006; 238: 192-199.
15. Chen M, Dang HD, Wang JY, Zhou C, Li SY, Wang WC, Zhao WF, Yang ZH, Zhong CY, Li GZ. Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined. Acta Radiol. 2008; 49: 602-610.
16. Coakley FV, Hricak H, Wefer AE, Speight JL, Kurhanewicz J, Roach M. Brachytherapy for prostate cancer: endorectal MR imaging of local treatment-related changes. Radiology 2001; 219: 817-821.
17. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, Zaloudek CJ, Nelson SJ, Carroll PR, Kurhanewicz J. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 1999; 213: 473-480.
18. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J. Magn. Reson. Imaging 2002; 16: 451-463.
19. Fütterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ, Vos P, Hulsbergen-Van de Kaa CA, Witjes JA, Krabbe PF, Heerschap A, Barentsz JO. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006; 241: 449-458.
20. Jung JA, Coakley FV, Vigneron DB, Swanson MG, Qayyum A,Weinberg V, Jones KD, Carroll PR, Kurhanewicz J. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 2004; 233: 701-708.
21. 1H magnetic resonance spectroscopic imaging. Magn. Reson. Med. 2000; 43: 17-22.
22. 3) spatial resolution. Radiology 1996; 198: 795-805.
23. Heijmink SW, Futterer JJ, Hambrock T, Takahashi S, Scheenen TW, Huisman HJ, Hulsbergen-Van de Kaa CA, Knipscheer BC, Kiemeney LA, Witjes JA, Barentsz JO. Prostate cancer: body-array versus endorectal coil MR imaging at 3 T-comparison of image quality, localization, and staging performance. Radiology 2007; 244: 184-195.
24. Kurhanewicz J, Vigneron DB, Hricak H, Parivar F, Nelson SJ, Shinohara K, Carroll PR. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Radiology 1996; 200: 489-496.
25. Costello LC, Franklin RB, Narayan P. Citrate in the diagnosis of prostate cancer. Prostate 1999; 38: 237-245.
26. 1H magnetic resonance spectroscopy and biochemical study. Magn. Reson. Med. 1993; 29: 149-157.
27. 1H magnetic resonance spectroscopic imaging. Chin. Med. Sci. J. 2007; 22: 238-242.
28. Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S, Muruganandham M, Ebora L, Kattan MW, Reuter VE, Scardino PT, Koutcher JA. Correlation of proton MR spectroscopic imaging with gleason score based on stepsection pathologic analysis after radical prostatectomy. Radiology 2005; 234: 804-814.
29. McNeal JE. Normal anatomy of the prostate and changes in benign prostatic hypertrophy and carcinoma. Semin. Ultrasound CT MR 1988; 9: 329-334.
30. Coakley FV, Kurhanewicz J, Lu Y, Jones KD, Swanson MG, Chang SD, Carroll PR, Hricak H. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 2002; 223: 91-97.
31. Fütterer JJ, Heijmink SW, Scheenen TW, Jager GJ, Hulsbergen-Van de Kaa CA, Witjes JA, Barentsz JO. Prostate cancer: local staging at 3-T endorectal MR imaging - early experience. Radiology 2005; 238: 184-191.
32. Scheenen TW, Heijmink SW, Roell SA, Hulsbergen-Van de Kaa CA, Knipscheer BC, Witjes JA, Barentsz JO, Heerschap A. Three-dimensional proton MR Spectroscopy of human prostate at 3 T without endorectal coil: feasibility. Radiology 2007; 245: 507-516.
33. Carlani M, Mancino S, Bonanno E, Finazzi Agrò E, Simonetti G. Combined morphological, [1H]-MR spectroscopic and contrast-enhanced imaging of human prostate cancer with a 3-Tesla scanner: preliminary experience. Radiol. Med. (Torino) 2008; 113: 670-688.
34. Alonzi R, Padhani AR, Allen C. Dynamic contrast enhanced MRI in prostate cancer. Eur. J. Radiol. 2007; 63: 335-350.
35. Noworolski SM, Henry RG, Vigneron DB, Kurhanewicz J. Dynamic contrast-enhanced MRI in normal and abnormal prostate tissues as defined by biopsy, MRI, and 3D MRSI. Magn. Reson. Med. 2005; 53: 249-255.
36. Padhani AR, Husband JE. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin. Radiol. 2001; 56: 607-620.
37. Rouvière O, Raudrant A, Ecochard R, Colin-Pangaud C, Pasquiou C, Bouvier R, Maréchal JM, Lyonnet D. Characterization of timeenhancement curves of benign and malignant prostate tissue at dynamic MR imaging. Eur Radiol. 2003; 13: 931-942.
38. Muramoto S, Uematsu H, Kimura H, Ishimori Y, Sadato N, Oyama N, Matsuda T, Kawamura Y, Yonekura Y, Okada K, Itoh H. Differentiation of prostate cancer from benign prostate hypertrophy using dual-echo dynamic contrast MR imaging. Eur. J. Radiol. 2002; 44: 52-58.
39. Ren J, Huan Y, Wang H, Chang YJ, Zhao HT, Ge YL, Liu Y, Yang Y. Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis. Clin. Radiol. 2008; 63: 153-159.
40. Benigni R, Giuliani A. Quantitative modeling and biology: the multivariate approach. Am. J. Physiol. 1994; 266: R1697-R1704.
41. Franke R. Theoretical Drug Design Methods. Elsevier: Amsterdam, 1984.
42. Scheenen TW, Klomp DW, Roll SA, Futterer JJ, Barentsz JO, Heerschap A. Fast acquisition-weighted three-dimensional proton MR spectroscopic imaging of the human prostate. Magn. Reson. Med. 2004; 52: 80-88.
43. Hoch J, Stern A. NMR Data Processing. Wiley and Sons: New York, 1996.
44. Bartella L, Thakur SB, Morris EA, Dershaw DD, Huang W, Chough E, Cruz MC, Liberman L. Enhancing nonmass lesions in breast: evaluation with proton (1H) MR spectroscopy. Radiology 2007; 245: 80-87.
45. Eriksson L, Johansson E, Kettaneh-Wold N, Wold S. Multi- and megavariate data analysis - principles and applications. In Multi- and Megavariate Data Analysis - Principles and Applications. Eriksson L, Johansson E, Kettaneh-Wold N, Wold S (eds). Umetrics Academy, Umea: Sweden, 2001.
46. Guilford J. Fundamental Statistics in Psychology and Education. McGraw Hill: New York, 1965.
47. Lebart L, Morineau A, Warwick KM. Multivariate Descriptive Statistical Analysis. Wiley and Sons: New York, 1984.
48. Wang L, Hricak H, Kattan MW, Chen HN, Kuroiwa K, Eisenberg HF, Scardino PT. Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. Radiology 2007; 242: 182-188.
49. Etzioni R, Penson DF, Legler JM, Di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J. Natl Cancer Inst. 2002; 94: 981-990.
50. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J. Natl Cancer Inst. 2003; 95: 868-878.
51. Jager GJ, Ruijter ET, van de Kaa CA, de la Rosette JJ, Oosterhof GO, Thornbury JR, Ruijs SH, Barentsz JO. Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology 1997; 203: 645-652.
52. Kurhanewicz J, Vigneron DB, Males RG, Swanson MG, Yu KK, Hricak H. The prostate: MR imaging and spectroscopy. Present and future. Radiol. Clin. North Am. 2000; 38: 115-138.
53. Shukla-Dave A, Hricak H, Kattan MW, Pucar D, Kuroiwa K, Chen HN, Spector J, Koutcher JA, Zakian KL, Scardino PT. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int. 2007; 99: 786-793.
54. Padhani AR, Gapinski CJ, Macvicar DA, Parker GJ, Suckling J, Revell PB, Leach MO, Dearnaley DP, Husband JE. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin. Radiol. 2000; 55: 99-109.
55. Checkley D, Tessier JJ, Kendrew J, Waterton JC, Wedge SR. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br. J. Cancer 2003; 89: 1889-1895.
56. van Dorsten FA, van der Graaf M, Engelbrecht MR, van Leenders GJ, Verhofstad A, Rijpkema M, de la Rosette JJ, Barentsz JO, Heerschap A. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J. Magn. Reson. Imaging 2004; 20: 279-287.
57. Sirabella P, Giuliani A, Colosimo A, Dippner JW. Deconvolving the climate effects on cod recruitment by principal component analysis and canonical correlation. Mar. Ecol. Prog. Ser. 2001; 218: 213-222.
58. Crescenzi M, Giuliani A. The main biological determinants of tumor line taxonomy elucidated by a principal component analysis of microarray data. FEBS Lett. 2001; 507: 114-118.
59. Nicholson JK, Lindon JC. Systems biology: metabonomics. Nature 2008; 455: 1054-1056.